Form 4: USANA Director Fleming Exercises Restricted Stock Units

USANA Health Sciences Director John Turman Fleming acquired 1,057 shares of common stock through the exercise of restricted stock units on October 23, 2025.

Summary

• John Turman Fleming, a Director of USANA Health Sciences Inc. (USNA), reported a transaction on October 23, 2025.
• Fleming acquired 1,057 shares of USANA common stock through the exercise of restricted stock units (RSUs).
• Each restricted stock unit represents a contingent right to receive one share of USNA common stock.
• Following this transaction, Fleming directly beneficially owns 6,315 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• After the exercise, Fleming directly beneficially owns 2,115 remaining restricted stock units.
• The remaining restricted stock units vest 25% on January 22, 2026, and April 23, 2026.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director is increasing their direct ownership of common stock, albeit through a routine RSU exercise. The transaction being under a 10b5-1 plan indicates it's not a discretionary market purchase, but it still reflects continued holding and conversion of equity compensation.

Positives

• The transaction increases Director John Turman Fleming's direct beneficial ownership of USANA common stock by 1,057 shares, signaling continued alignment with shareholder interests.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned, non-discretionary acquisition of shares.

Future Outlook

Remaining restricted stock units held by Director John Turman Fleming are scheduled to vest 25% on January 22, 2026, and 25% on April 23, 2026.

Industry Context

This is a routine insider transaction related to equity compensation, common across various industries for directors and executives, and does not directly reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns management interests with shareholder value, though it's a routine compensation event.

Next Steps

• Future vesting of remaining restricted stock units on January 22, 2026, and April 23, 2026.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the exercise of restricted stock units by a director, which was pre-scheduled under a Rule 10b5-1 plan. Such transactions are common for executive compensation and do not typically signal a significant change in company fundamentals or future prospects. While it increases the director's direct ownership, it is not a discretionary market purchase and therefore does not provide a strong signal for a 'buy' or 'sell' recommendation. Investors should 'hold' and consider this a neutral event in the context of their broader investment thesis for USANA Health Sciences.

Keywords

USANA Health Sciences, USNA, Insider Transaction, Form 4, Restricted Stock Units, Director Ownership, Equity Compensation, Rule 10b5-1